Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Biotech
ASCO: BMS' bispecific ADC puts TROP2 drugs on notice
BMS' CMO Cristian Massacesi is already thinking about potential combinations of the EGFRxHER3 bispecific ADC with its BioNTech-partnered pumitamig.
Angus Liu
Jun 2, 2026 8:00am
BMS' ADC hits primary endpoints in phase 3 breast cancer trial
Feb 26, 2026 9:08am
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
May 6, 2025 9:40am
BioNTech posts overall survival data on would-be Keytruda killer
Dec 10, 2024 9:00am
Death drives Lyell to take 2-track approach to dose escalation
Jun 26, 2024 10:00am
Gilead draws up $20M pact with cancer biotech Cartography
May 28, 2024 10:26am
